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Background: Biological treatments are considered as additional options for the treatment of 
resistant unipolar depression. Controversial data exist about the efficacy and tolerability of three 
of the most used somatic treatments: electroconvulsive therapy (ECT), transcranial magnetic 
stimulation (rTMS), and deep transcranial magnetic stimulation (deepTMS). The aim of this 
review is to investigate and compare the efficacy and tolerability of these three techniques in 
drug-free patients with pharmacoresistant unipolar depression.
Methods: Three independent reviewers extracted data and assessed the quality of method-
ological reporting of selected studies. The first outcome was the clinical response to the three 
different techniques defined as a percentage improvement of Hamilton Depression Rating Scale 
(HDRS). The second outcome was the evaluation of their neuropsychological effects. The third 
outcome was the evaluation of the number of remitted patients; remission was defined as an 
absolute HDRS-24 score of #11 or as an absolute HDRS-17 score of #8. Tolerability was the 
fourth outcome; it was evaluated by examining the number of dropped-out patients.
Results: The comparative evaluation of HDRS percentage variations shows ECT as the most 
effective method after 4 weeks of therapy; on the other hand, a better efficacy is obtainable by 
deepTMS after 2 weeks of therapy. DeepTMS is the technique that gives the best improvement 
of cognitive performances. The percentage of remitted patients obtained with ECT treatment is 
the same obtained in the deepTMS group. Both techniques have a remitted patients percentage 
two times larger than the rTMS. DeepTMS shows a tolerability, measured by the number of 
dropped-out patients, worse than ECT.
Conclusion: Our investigation confirms the great therapeutic power of ECT. DeepTMS seems 
to be the only therapy that provides a substantial improvement of both depressive symptoms and 
cognitive performances; nevertheless it is characterized by a poor tolerability. rTMS seems to 
provide a better tolerability for patients, but its therapeutic efficacy is lower. Considering the 
small therapeutic efficacy of deepTMS in the last 2 weeks of treatment, it could be reasonable 
to shorten the standard period of deepTMS treatment from 4 to 2 weeks, expecting a reduction 
of dropped-out patients and thus optimizing the treatment outcome.
Keywords: deep transcranial magnetic stimulation, transcranial magnetic stimulation, 
 electroconvulsive therapy, pharmacoresistant unipolar depression
Introduction
Major depressive disorder (MDD) is a chronic disorder characterized by single and recur-
rent episodes. As established by converging neuropsychological, biochemical, neuroim-
aging, and postmortem evidence, depression is unlikely to be a disease of a single brain 
region or neurotransmitter system. Rather, it is now generally viewed as a system-level 
disorder affecting integrated pathways.1–5 Notwithstanding the  therapeutic armament 
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available to clinicians, approximately 30% of patients remain 
symptomatic despite standard interventions; this group is 
considered to have treatment-resistant depression.6,7
Biological treatments are considered additional options 
for the treatment of resistant bipolar depression.  Controversial 
data exist about the efficacy and tolerability of three of the 
most-used somatic treatments: electroconvulsive therapy 
(ECT), transcranial magnetic stimulation (rTMS), and deep 
transcranial magnetic stimulation (deepTMS).
ECT is considered an effective alternative for pharmaco-
resistant patients, even if it necessitates administering general 
anesthetic, induces a seizure, or may cause memory and 
 learning impairments.8–10 rTMS is a noninvasive technique 
used to apply magnetic pulses to the brain through an elec-
tromagnetic coil placed above the patient’s scalp, inducing 
electrical activity in the underlying cortical  tissue that can result 
in localized neuronal depolarization; it has been proposed as 
a refined alternative.11 DeepTMS is currently being evaluated 
as a treatment option in major depression and has been shown 
to be a safe and effective procedure.12–16 DeepTMS coils are 
designed to maximize the electrical field deep in the brain by 
the summation of separate fields projected into the skull from 
several points around its periphery, while minimizing the accu-
mulation of electrical charge on the surface of the brain.17
The aim of this review is to investigate and to compare the 
efficacy and tolerability of these three techniques in patients 
with pharmacoresistant unipolar depression. We performed a 
systematic comparison of the results of those studies where 
these three techniques were used to treat unipolar drug-free 
depressed patients. This kind of selection was made to obtain 
the best evaluation of the therapeutic efficacy of ECT, rTMS, 
and deepTMS, considering the complete absence of pharma-
cologic interference.
Methods
The first step of this study was a selective literature search. 
Three independent reviewers extracted data and assessed the 
quality of methodological reporting of selected studies using 
data extraction forms. Our key search terms were major 
depression, resistant depression, transcranial magnetic stimu-
lation, rTMS, TMS, deepTMS, deep transcranial magnetic 
stimulation, ECT, and electroconvulsive therapy.  Prospective 
studies evaluating the effects of the three techniques on 
mood and cognition in patients with major depression were 
included. Inclusion criteria for studies were:
1. articles written in English
2. diagnosis of MDD according to the Diagnostical and 
 Statistical Manual of Mental Disorders III, IV, or IV-TR18
3. an explicit definition of treatment-resistant depression that 
included at least one failed trial of an antidepressant drug
4. patients not treated with any kind of  psychotropic 
drug (with the exception of occasional use of 
 benzodiaz epines)
5. rTMS given at high frequencies (.1 Hz) and delivered 
to left dorsolateral prefrontal cortex (DLPFC)
6. use of deepTMS at high frequencies (.1 Hz) at any 
localization
7. use of ECT given at any intensity and localization
8. mood effects assessed by the same continuous mood 
scale: Hamilton Depression Rating Scale (HDRS) 17 or 
24 items
9. studies published within the last 20 years.
The first outcome was the clinical response, defined 
as a percentage improvement of HDRS evaluated at three 
 different timepoints: pretreatment (T0), after 2 weeks of 
 treatment (T1), and after 4 weeks of treatment (T2). The 
second outcome was the evaluation of neuropsychological 
effects of the three different techniques. The third outcome 
was the evaluation of the number of remitted patients. 
 Tolerability was the fourth outcome. It was evaluated by 
examining the number of dropped-out patients.
Data analysis
The sample was divided into three groups: (1) patients 
treated with ECT (160 patients), (2) patients treated with 
rTMS (211 patients), and (3) patients treated with deepTMS 
(58 patients) (Figure 1).
Clinical response
Clinical response was defined as a decrease on HDRS. 
The Fisher–Snedecor F test was used to test the 
 heterogeneity of the data. Using this test, the null hypothesis 
ECT: 160
rTMS: 211
deepTMS: 58
Figure 1 Number of enrolled patients.
Abbreviations: ECT, electroconvulsion therapy; rTMS, transcranial magnetic 
stimulation; deepTMS, deep transcranial magnetic stimulation.
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of the equality of the averages was refused (P # 0.05; 
confidence interval [CI] 95%).
We calculated the percentage variation of the HDRS 
average scores between baseline (T0), 2 weeks of treatment 
(T1), and 4 weeks of treatment (T2) with each technique. 
Because of the fact that 307 patients were evaluated with 
HDRS-24 items and 122 patients were evaluated with HDRS-
17 items, the group of ECT-treated patients was divided into 
two subgroups: one of 96 patients where symptoms were 
evaluated with HDRS-24, and one of 64 patients where 
symptoms were evaluated with HDRS-17; the group of 
rTMS-treated patients was also divided into two subgroups: 
one of 153 patients where symptoms were evaluated with 
HDRS-24, and one of 58 patients where symptoms were 
evaluated with HDRS-17.
In all patients treated with deepTMS, depressive symp-
toms were evaluated with HDRS-24 items.
Neuropsychological effects
We calculated the percentage variation of average scores of 
the Mini-Mental State Examination (MMSE),19 Weschler 
Adult Intelligence Scale-Revised (WAIS-R),20 Wechsler 
Memory Scale (WMS),21 and Rivermead Behavioral Memory 
Test (RBMT)22 after 2 and 4 weeks of treatment with ECT 
and rTMS. We also calculated the percentage variation of 
the Cambridge Neuropsychological Test Automated Battery 
(CANTAB)23 average scores after 2 and 4 weeks of treatment 
with deepTMS.
Remission rate
Remission was defined as an absolute HDRS-24 score of #11 
or as an absolute HDRS-17 score of #8.
Tolerability
The fourth outcome of the study was to evaluate the tolerability 
of each technique. To do this, we calculated the percentage 
of dropped-out patients in each group of patients.
Results
Included studies
Only nine studies met our inclusion criteria (Table 1). A 
total of 160 patients were treated with ECT.24–27 Among 
these, the standard bifrontotemporal (bilateral) placement 
of electrodes was used in 50 patients,28 the d’Elia placement 
of electrodes was used in 46,29 and treatment began with 
right unilateral ECT in 64. If there was no antidepressant 
response after six ECT treatments, bilateral ECT was per-
formed (Table 1). Two hundred and eleven patients were 
treated with rTMS.25,26,30–32 Of these, 28 received ten ses-
sions of rTMS treatment, 40 received 20 sessions of rTMS 
treatment, and 143 received 30 sessions of rTMS treatment 
(Table 1).  Fifty-eight patients were treated with deepTMS 
(Table 1).13,14
In the 96 patients treated by Sackeim et al, the seizure 
threshold was quantified at the time of the first and last 
treatment with the empirical titration procedure.24 Electrical 
stimulations were administered at subconvulsive levels of 
increasingly higher intensity until a generalized tonic-clonic 
seizure of adequate duration was induced. The frequency 
of brief pulses (range, 20–140 Hz) was the primary elec-
trical variable manipulated, because the device used for 
 electroconvulsive therapy had greater range and sensitivity 
in the frequency domain than in pulse width, current inten-
sity, or in the duration of the stimulus. The tourniquet method 
and two channels of prefrontal electroencephalography 
Table 1 Included studies
Study Technique Stimulation Patients, n Duration
Sackeim et al24 ECT Right unilateral and bilateral; convulsive threshold or 2.5 times threshold 96 4 weeks
Rosa et al25 ECT Right unilateral at a mean charge of 4.5 times the threshold. If there  
was no antidepressant response after 2 weeks, bilateral ECT was  
performed. At 1.5 times the threshold
15 4 weeks
Grunhaus et al26 ECT Unilateral up to 2.5 times the threshold. If there was no antidepressant  
response after 2 weeks, bilateral ECT was performed
20 4 weeks
Dannon and Grunhaus27ECT Unilateral up to 2.5 times the threshold. If there was no antidepressant  
response after 2 weeks, bilateral ECT was performed
29 4 weeks
O’Reardon et al30 rTMS 10 Hz; left DLPFC; 120% of motor threshold 143 6 weeks
Berman et al31 rTMS 20 Hz; left DLPFC; 80% of motor threshold 10 2 weeks
Grunhaus et al26 rTMS 10 Hz; left DLPFC; 90% of motor threshold 20 4 weeks
Baeken et al32 rTMS 10 Hz; left DLPFC; 110% of motor threshold 18 2 weeks
Rosa et al25 rTMS 10 Hz; left DLPFC; 100% of motor threshold 20 4 weeks
Levkovitz et al13 DeepTMS 20 Hz; left and bilateral DLPFC; 110% and 120% of motor threshold 53 4 weeks
Rosenberg et al14 DeepTMS 20 Hz; left DLPFC; 120% of motor threshold 5 4 weeks
Abbreviations: ECT, electroconvulsion therapy; rTMS, transcranial magnetic stimulation; DLPFC, dorsolateral prefrontal cortex.
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were used to assess the duration of seizures. In the first 
five treatments, the criterion for an adequate generalized 
seizure was at least 25 seconds of tonic-clonic movement 
or 30 seconds of electroencephalographic seizure activity. 
After the fifth treatment, the cut-off values were reduced 
to 20 and 25 seconds, respectively. This change was made 
to account for the spontaneous decrease in seizure duration 
that occurs during electroconvulsive therapy. Forty-six of 
these patients received a low-dose treatment, where the 
electrical intensity that resulted in a generalized seizure in 
the first session was the one administered at the next treat-
ment. If this intensity proved adequate, a lower intensity 
was used for the next treatment. In the low-dose groups, this 
procedure was followed throughout the treatment course. 
The other 50 patients received high-dose treatment, where 
at the second and subsequent sessions each patient received 
an electrical intensity stimulus 2.5 times the threshold 
identified in the first treatment, except that at the time of 
the last treatment the seizure threshold was determined 
again (Table 1).
In the 29 patients treated by Dannon et al,27 seizure 
threshold was determined for all of them during the first ECT 
using Sackeim et al’s method.33 The following ECT treat-
ments were performed at 2.5 times the threshold energy and 
charge was titrated upward every second or third treatment to 
maintain a seizure length of 25 seconds. Seizure duration was 
monitored with both the cuff and electroencephalographic 
methods (Table 1).
O’Reardon et al performed a double-blind, multicenter 
study on 301 medication-free patients with major depres-
sion who had not benefited from prior treatment.30 These 
patients were randomized to active or sham TMS  conditions. 
Sessions were conducted five times per week with TMS 
at 10 pulses/second, 120% of motor threshold (MT), 
3000 pulses/session, for 4–6 weeks. The MT estimation was 
repeated weekly by visual observation of thumb or other 
finger movement (Table 1).
Rosa et al performed a study on 35 patients aged between 
18 and 65 years.25 Patients were randomized to receive ECT or 
rTMS to the left DLPFC according to a computer- generated 
list. rTMS sessions were performed five times per week for 
4 weeks (total of 20 sessions). The following parameters 
were used: site of stimulation, left DLPFC; intensity, 100% 
MT; frequency, 10 Hz; trains of 10 seconds and intertrain 
interval of 20 seconds; 25 trains per session. Therefore, a 
total of 2500 pulses were administered each session (overall 
total of 50,000 pulses). MT was defined as the lowest TMS 
intensity required to elicit motor-evoked potentials (MEP) of 
0.05 mV in the contralateral resting abduttor pollicis  brevis 
(APB) muscle in at least five of ten trials with the coil over the 
optimal scalp position. The ECT treatment began with right 
unilateral ECT. If there was no antidepressant response after 
2 weeks, bilateral ECT was performed. In the first treatment, 
seizure threshold was calculated according to the method of 
limits.34 In the following treatments, a mean charge of 4.5 
times the threshold was given three times a week (Monday, 
Wednesday, and Friday). If a patient was transferred to 
bilateral ECT, a mean charge of 1.5 times the threshold was 
given (Table 1).
In the study by Grunhaus et al, 40 patients were  included.26 
Patients were assigned to the rTMS or ECT groups. ECT was 
performed according to established protocols. The titration 
of electrical charge was performed in all cases following the 
method of limits during the first ECT treatment. Additional 
treatments were performed at 2.5-times threshold charge. 
Treatments with ECT were continued until the treating 
physician considered that a therapeutic response had been 
obtained or that no further therapeutic benefit was to be 
expected. Patients included in this study were required to 
have had at least six ECT treatments, unless the course was 
suspended due to an early therapeutic response. Thirteen of 
these patients were treated unilaterally, and seven patients 
were treated bilaterally. Patients switching from unilateral to 
bilateral treatment received a mean of five additional bilat-
eral treatments. Repetitive TMS was performed over the left 
DLPFC at 90% MT. Patients were treated with 20 sessions 
(five times per week for 4 weeks) of 10 Hz (1200 pulses 
per treatment day) at 90% MT. MT was determined in all 
individuals following the methods described by Rossini and 
Rossi.35 The tapering process was completed in all cases 
within 3 days (Table 1).
In the study by Berman et al, 20 depressed subjects were 
assigned in a randomized double-blind manner to receive 
either active (20 × 2 second trains of 20 Hz stimulation 
with 58 second intervals, delivered at 80% MT with the 
figure-of-eight coil positioned over the left DLPFC) or sham 
rTMS.31 MT was determined daily and was defined at the 
point of maximal stimulation for the right APB or other hand 
muscles, as visually detected. These sequences were applied 
during ten consecutive weekdays (Table 1).
In the study conducted by Baeken et al, 19 patients were 
treated with rTMS.32 Before each application, the resting 
MT of each subject was determined using electromyography. 
A stimulation intensity of 110% of the subject’s MT of the 
right APB muscle was used (Table 1). One patient dropped 
out before the second week of treatment.
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In the studies by Levkovitz et al and Rosenberg et al, 
each subject was treated with one of three versions of the 
H-coil (H1, H2, and H1L), similar in external appearance 
and acoustic properties when actively pulsed.13,14 The 
H1-coil was designed to stimulate deep prefrontal brain 
regions, preferentially in the left hemisphere. Fifteen patients 
received the treatment with H1-coil at 120% of the measured 
MT. The H2-coil was designed to stimulate deep prefron-
tal brain regions bilaterally, with no lateral preference. 
18 patients received the treatment with H2-coil at 120% of 
the measured MT. The H1L-coil was designed to stimulate 
deep prefrontal brain regions unilaterally, exclusively in the 
left hemisphere. Six patients were treated with H1L-coil at 
110% of the measured MT while ten patients were treated 
with H1L-coil at 120% of the measured MT. To localize 
the optimal placement, suprathreshold intensities were 
applied around the hand motor area (tested at increments 
of 1 cm) and the spot inducing the greatest motor response 
was marked. To refine the “hot” spot for APB activation, 
the intensity was reduced until the MEP was ,100 mV and 
motor responses were tested around the marked spot search-
ing for placement for inducing the maximal response. The 
MT was measured by using single pulse mode, applying one 
pulse every 5–10 seconds and recording electrical activity in 
the APB by using surface electrodes. MT was defined before 
each daily session as the lowest intensity of stimulation able 
to produce MEP of at least 50 mV in three of six trials. The 
coil was placed 5.5 cm anterior to the motor spot (over the 
prefrontal cortex). The treatment was delivered in trains 
of 20 Hz, 5 days per week for 4 weeks. Each TMS session 
consisted of 42, 2-second trains, with an intertrain interval 
of 20 seconds (ie, a total of 1680 pulses delivered during a 
15-minute daily session) (Figure 1).
A total of 96 ECT-treated patients were assessed by 
HDRS-24 items before the treatment, after six ECT treat-
ments, and at the end of the treatment to evaluate depressive 
symptoms; 35 ECT-treated patients by HDRS-17 items before 
the treatment, after six ECT treatments, and at the end of the 
treatment; 29 ECT-treated patients by HDRS-17 items before 
and at the end of the treatment.
Among the patients treated with rTMS, 143 were assessed 
by HDRS-24 items before the treatment, after 4 weeks, and 
after 6 weeks of treatment to evaluate depressive symptoms; 
ten patients were assessed by HDRS-24 items before the 
treatment and after 2 weeks; 19 patients were assessed by 
HDRS-17 items before the treatment and after 2 weeks. Forty 
patients received HDRS-17 items before the treatment, after 
2 weeks, and after 4 weeks of treatment.
All 58 patients treated with deepTMS were assessed by 
HRSD-24 items before the treatment, after 2 weeks, and after 
4 weeks of treatment to evaluate depressive symptoms.
All 160 patients treated with ECT were assessed by neu-
ropsychological tests focusing on anterograde and retrograde 
memory. Of these patients, 116 received modified versions 
of the MMSE before the treatment, after six ECT treatments, 
and at the end of the course. Of these, 29 received modified 
versions of the MMSE before and at the end of the treatment 
and 15 received several tests including subsections of the 
WAIS-R (vocabulary and cubes), subsections of the WMS 
(digit span), and the RBMT.
A total of 40 patients treated with rTMS received neuropsy-
chological tests focusing on anterograde and retrograde mem-
ory; 20 received MMSE to evaluate cognitive condition before 
and after the treatment while the other 20 patients received tests 
including subsections of the WAIS-R (vocabulary and cubes), 
subsections of the WMS (digit span), and the RBMT.
All 53 patients treated with deepTMS received comput-
erized cognitive assessments using the CANTAB tests at 
baseline, after 2 weeks, and after 4 weeks of treatment. Each 
subject was administered the tests in a pseudo-randomized 
fashion and in a controlled environment. The neuropsycho-
logical battery was designed to differentiate dorsolateral, 
superior medial, and ventrolateral functions potentially 
affected by deepTMS treatment.
Clinical response
Clinical response from T0 to T1
In ECT-treated patients, HDRS-24 decreased by 22.83% from 
T0 to T1 (Figure 3), while HRSD-17 decreased by 30.00%. 
In rTMS-treated patients, HDRS-24 decreased by 33.69% 
from T0 to T1, while HRSD-17 decreased by 32.37%. In 
deepTMS-treated patients, HDRS-24 decreased by 43.81% 
from T0 to T1 (Figure 3).
These results indicate that after 2 weeks of treatment, 
deepTMS seems to be more effective than ECT and rTMS 
in decreasing HDRS-24 score; moreover, ECT seems to be 
more effective than rTMS.
Clinical response from T1 to T2
In ECT-treated patients, HDRS-24 decreased by 21.60% from 
T1 to T2 (Figure 3), while HDRS-17 decreased by 18.61%. In 
rTMS-treated patients, HDRS-17 decreased by 12.55% from 
T1 to T2. In deepTMS-treated patients, HDRS-24 decreased 
by 0.38% from T1 to T2 (Figure 3).
These results suggest that between the second and 
fourth week of treatment ECT is more effective than rTMS 
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Figure 2 HDRS-24 % decrease in patients treated with ECT, rTMS, and deepTMS from baseline to the fourth week of treatment.
Abbreviations: HDRS, Hamilton Depression Rating Scale; ECT, electroconvulsion therapy; rTMS, transcranial magnetic stimulation; deepTMS, deep transcranial magnetic 
stimulation.
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Figure 3 HDRS-24 % decrease in patients treated with ECT and deepTMS after 2 and 4 weeks of treatment.
Abbreviations: HDRS, Hamilton Depression Rating Scale; ECT, electroconvulsion therapy; deepTMS, deep transcranial magnetic stimulation.
and deepTMS in decreasing HDRS-24 score; moreover, 
rTMS is more effective than deepTMS.
Clinical response from T0 to T2
In ECT-treated patients, HDRS-24 decreased by 56.96% 
from T0 to T2 (Figures 2 and 3), while HDRS-17 decreased 
by 42.84%. In rTMS-treated patients, HDRS-24 decreased 
by 22.25% from T0 to T2 (Figure 2), while HDRS-17 
decreased by 42.56%. In deepTMS-treated patients, HDRS-
24 decreased by 43.59% from T0 to T2 (Figures 2 and 3).
These results suggest that after 4 weeks of treatment ECT 
is more effective than deepTMS and rTMS in decreasing 
HDRS-24 score; moreover, deepTMS is more effective than 
rTMS (Figure 2).
Neuropsychological effects
Cognitive condition was the second outcome considered 
in this study. The cognitive assessment was made using 
 different evaluation methods: MMSE, CANTAB, WAIS-R, 
WMS, and RBMT.
Neuropsychological effects in ECT-treated patients
Fifteen of the ECT-treated patients presented the following 
percentage variations of average scores (Figures 4 and 5):
•	 Total vocabulary (WAIS-R): T0–T1: −7.59%; 
T1–T2: +4.81%; T0–T2: −3.14%.
•	 Total cubes (WAIS-R): T0–T1: −1.88%; T1–T2: +9.61%; 
T0–T2: +7.54.
•	 Estimated IQ (WAIS-R): T0–T1: −0.10%; T1–T2: −0.10%; 
T0–T2: −0.21%.
•	 Direct Digits (WMS): T0–T1: +10.39%; T1–T2: −23.52%; 
T0–T2: −15.58%.
•	 Indirect Digits (WMS): T0–T1: −18.18%; T1–T2: +4.48%; 
T0–T2: −14.54%.
•	 Numbers (WAIS-R): T0–T1: −1.51%; T1–T2: −13.84%; 
T0–T2: −15.15%.
•	 RBMT profile: T0–T1: −22.53%; T1–T2: +13.63%; 
T0–T2: −11.97%.
Of the ECT-treated patients, 145 were evaluated by 
MMSE from T0 to T2. The average score increased by 
7.01% (Figure 5).
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Figure 4 Cognitive variations in patients treated with ECT and rTMS from T0 to T1 (2 weeks of treatment).
Abbreviations: ECT, electroconvulsion therapy; RBMT, Rivermead Behavioral Memory Test; rTMS, transcranial magnetic stimulation; wAIS, weschler Adult Intelligence 
Scale; wAIS-R, weschler Adult Intelligence Scale-Revised; wMS, wechsler Memory Scale.
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Figure 5 Cognitive variations in patients treated with ECT and rTMS from T0 to T2 (4 weeks of treatment).
Abbreviations: ECT, electroconvulsion therapy; RBMT, Rivermead Behavioral Memory Test; rTMS, transcranial magnetic stimulation; wAIS, weschler Adult Intelligence 
Scale; wAIS-R, weschler Adult Intelligence Scale-Revised; wMS, wechsler Memory Scale.
Neuropsychological effects in rTMS treated patients
Twenty of the rTMS-treated patients were evaluated by MMSE 
from T0 to T2. The average score increased by 0.71% (Fig-
ure 5). The 20 rTMS-treated patients presented the following 
percentage variations of average scores  (Figures 4 and 5):
•	 Total vocabulary (WAIS-R): T0–T1: +12.80%; 
T1–T2: +0.23%; T0–T2: +13.06%.
•	 Total cubes (WAIS-R): T0–T1: −2.21%; T1–T2: +24.43%; 
T0–T2: +21.68%.
•	 Estimated IQ (WAIS-R): T0–T1: +2.61%; T1–T2: +2.12%; 
T0–T2: +4.71%.
•	 Direct Digits (WMS): T0–T1: 0.00%; T1–T2: −3.17%; 
T0–T2: −3.17%.
•	 Indirect Digits (WMS): T0–T1: +10.41%; T1–T2: 0.00%; 
T0–T2: +10.41%.
•	 Numbers (WAIS-R): T0–T1: +1.75%; T1–T2: +0.86%; 
T0–T2: +2.63%.
•	 RBMT prof ile: T0–T1: +9.14%; T1–T2: −3.35%; 
T0–T2: +5.48%.
Neuropsychological effects in deepTMS  
treated patients
A total of 53 patients treated with deepTMS received CAN-
TAB neuropsychological assessment at T0 and T2. They 
presented the following percentage variations of average 
scores:
•	 Sustained attention: +2.29%.
•	 Visuospatial memory: +15.72%.
•	 Cognitive planning: +6.17%.
•	 Spatial memory: +15.89%.
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Remission rate
Remission rate was the third outcome of the study.  Remission 
was defined as an HDRS-24 score of #11 or as an HDRS-
17 score of #8. Remission was achieved by 28.57% of patients 
treated with ECT, 14.21% of patients treated with rTMS, 
and 29.31% of patients treated with deepTMS (Figure 6). 
These results suggest that deepTMS and ECT have a compa-
rable efficacy in achieving remission and that both deepTMS 
and ECT seem to be more effective than rTMS in achieving 
remission after 4 weeks of treatment.
Tolerability
Tolerability, measured by the number of dropped-out 
patients, was the fourth outcome that we highlighted in this 
study. The following drop-out rates are shown in Figure 7: 
9/169 patients dropped out from ECT trials (13.04%), 
16/227 patients dropped out from rTMS trials (7.04%), and 
14/58 patients dropped out from deepTMS trials (19.44%).
These results suggest that rTMS is more tolerable than 
ECT and deepTMS; moreover, that ECT is more tolerable 
than deepTMS.
Discussion
The aim of this review was to compare the efficacy and the 
tolerability of ECT, rTMS, and deepTMS in pharmacoresis-
tant depressed drug-free patients.
The comparative evaluation of the percentage variations of 
HDRS average scores from T0 to T2 indicates ECT as the best 
therapy, followed by deepTMS and rTMS (Figures 2 and 3). 
The percentage of remitted patients obtained with ECT 
treatment is the same obtained in the deepTMS group. 
Both techniques showed a percentage of remitted patients 
two times higher than rTMS (Figure 6). Even if the percentage 
of remitted patients was very similar, deepTMS showed a 
tolerability, measured by the number of dropped-out patients, 
worse than ECT (Figure 7). Finally, deepTMS showed all its 
therapeutic potential within the first two weeks of treatment, 
with almost no further activity from the second to the fourth 
week of treatment (Figure 3).
Considering the small therapeutic efficacy of deepTMS 
in the last 2 weeks of treatment, it could be reasonable to 
shorten the standard period of deepTMS treatment from 4 to 
2 weeks, expecting a reduction of dropped-out patients and 
thus optimizing the treatment outcome.
To our knowledge, data about the relapse risk related to 
the duration of deepTMS treatment are missing. Such data 
are needed to establish the best duration of therapy. In fact, 
data we presented suggest that deepTMS is absolutely the 
most effective therapy after 2 weeks of treatment.
Regarding cognitive performances, our results stimulate 
some considerations. The cognitive performances of ECT-
treated patients decreased in the first 2 weeks (Figure 4), and 
slightly increased at the end of treatment (Figure 5). This 
was different from what happened in patients on rTMS and 
deepTMS therapy, whose cognitive performances had a stable 
improvement. Among the three techniques, deepTMS seems 
to give the best benefits in terms of cognitive performance 
improvements.
In conclusion, our investigation confirms the great 
therapeutic power of ECT. Nevertheless, this technique has 
 different drawbacks: it needs hospitalization (which may 
be very expensive), it necessitates administering general 
 anesthetic, induces a seizure, and may cause cognitive 
 impairments. rTMS provides better tolerability for the 
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Figure 6 Percentage of remitted patients.
Abbreviations: ECT, electroconvulsion therapy; rTMS, transcranial magnetic stimulation; deepTMS, deep transcranial magnetic stimulation.
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patients but its therapeutic efficacy is lower. DeepTMS seems 
to be the only therapy (among the three therapies we analyzed 
in this review) that provides a substantial improvement in both 
depressive symptoms and cognitive performances; neverthe-
less, it is characterized by poor tolerability (greatest number 
of drop-out patients), which could potentially be avoided by 
reducing the duration of the treatment.
Our investigation has some limitations. The first of these 
is the use of HDRS as the only method of evaluating the 
clinical response of depression. HDRS contains a number 
of items focused on anxiety and somatic symptoms that do 
not allow capture of the most specific depressive symptoms. 
Lack of data regarding the long-term effects of rTMS and 
deepTMS limits the completeness of our investigation. 
Some relevant trials may have been unintentionally missed 
during the literature search. The rigorous inclusion crite-
ria may represent both a weakness and a strength of our 
study. In fact, the difficulty in collecting a large number of 
patients and the disproportionate size of the three groups 
of patients represent an important limitation. On the other 
hand, rigorous selection provides a better evaluation of the 
real efficacy of each technique, considering the complete 
absence of pharmacologic interference. Finally, we are 
conscious that therapeutic responses in double-blind studies 
are markedly lower than in open-label studies; the absence 
of double-blind studies using ECT or deepTMS in drug-
free unipolar depressed patients limits the possibility of 
achieving a definitive conclusion.
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